Bagchi Intellectual Property Law

Attorney Mayukh Sircar to lead new Intellectual Property Law focus Bagchi Law was founded on the core belief that commercial business clients deserve the expertise of a large law firm, coupled with the care and agile nature of a boutique practice. Today Bagchi Law is announcing the launch of a new business unit that will…

Read More

Bagchi Law is excited to announce our firm has added two new attorneys to the team. Tyler Demasky and Amanda Frazer-Collins recently joined our Chapel Hill law firm, and both will assist in our mission of serving our clients with the expertise of a big law firm, coupled with the care and agile nature of a boutique practice.

Read More

A crisis comes in all forms. Some are company-specific, while others are industry-specific. They can also be specific to geographical location or global. Regardless of the type of crisis, the Chief Financial Officer or CFO plays an important role, if not the most crucial role during these times.

Read More

In Part I of our Startup Tax Issues series, we discussed how to avoid penalties with valuations. But what about issues related to 83(b) elections? Startup founders or other service providers receiving restricted stock should strongly consider making an 83(b) election in the year the restricted stock is granted.

Read More

Filing taxes can be intimidating, but it’s as inevitable as death. Tax rules are complicated, subject to change, and frequently poorly written. Early-stage startup taxation is a relatively limited field and this is good news for founders. Four topics makeup about 60-80% of founder tax issues. In this two-part blog series, we will address common…

Read More

In 2013, there was a slowdown in clinical trials due to clinical trial litigation. Afterward, India experienced an upward trend. Read more about the history of clinical trials and the risks in part I and part II of this series. There are several reasons behind the positive growth in clinical phase 1 and phase 2…

Read More

Although India has made adjustments to match global clinical trial regulation standards, the country still has some work to do. Several grey areas still need to be addressed. In some cases, regulatory authorities are the solution. Other issues require industry practices derived from trial and error. This unfortunately raises significant risk and liability questions. Clinical…

Read More